ProQR ( (PRQR) ) has provided an announcement.
ProQR Therapeutics announced its financial and operational results for the year ending December 31, 2024, highlighting significant advancements in its Axiomer RNA editing pipeline. The company is on track to submit a Clinical Trial Application for its lead program, AX-0810, in Q2 2025, with the first clinical data expected in Q4 2025. ProQR’s strategic partnerships, including a $3.9 billion collaboration with Eli Lilly, and recent financial activities, such as an €82.1 million public offering, have fortified its financial position, providing sufficient runway into mid-2027. The company also expanded its collaboration with the Rett Syndrome Research Trust and appointed Dr. Peter A. Beal as Chief ADAR Scientist to further develop its RNA editing platform.
More about ProQR
ProQR Therapeutics is a biotechnology company focused on developing transformative RNA therapies using its proprietary Axiomer RNA editing technology. The company aims to address both rare and prevalent diseases by utilizing the cell’s own editing machinery, ADAR, to make specific nucleotide edits in RNA, potentially creating a new class of medicines.
YTD Price Performance: -32.48%
Average Trading Volume: 414,691
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $190.9M
Learn more about PRQR stock on TipRanks’ Stock Analysis page.